Asset Details
Do you wish to reserve the book?
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
Do you wish to request the book?
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
2020
Overview
Over the past decade, immune checkpoint inhibitors (ICI) have proven to be promising agents in a number of solid tumor malignancies. Pembrolizumab and nivolumab are ICIs that target programmed cell death protein 1 and both have been approved by the US Food and Drug Administration for the treatment of microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC). In MSI-H/dMMR CRC, these agents were found to have considerable antitumor activity and are now used in the treatment of this disease. However, MSI-H/dMMR tumors account for only 5% of metastatic CRC and the remaining patients are identified as being microsatellite stable/DNA mismatch repair proficient (MSS/pMMR). In MSS/pMMR CRC, ICIs were found to have no antitumor activity and they are not currently used in the treatment of the disease. However, ongoing research is expanding our knowledge of how the human immune system interacts with cancer cells. Identifying mechanisms to improve our immune response to MSS/pMMR CRC is of utmost importance. In this review, we discuss available clinical data and the emerging role of immune-based strategies to overcome the resistance to ICI therapy in the treatment of MSS/pMMR CRC.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Adenocarcinoma - drug therapy
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antigens
/ Antineoplastic Agents, Immunological - therapeutic use
/ Biomedical and Life Sciences
/ Colorectal Neoplasms - drug therapy
/ DNA
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - therapeutic use
/ Ligands
/ Mutation
/ Programmed Cell Death 1 Receptor - antagonists & inhibitors
/ Proteins
/ Tumors
